228. 閉塞性細気管支炎 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 97 / 薬物数 : 118 - (DrugBank : 32) / 標的遺伝子数 : 33 - 標的パスウェイ数 : 156
薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。
5-Methyl-1-Phenyl-2-1-(H)-Pyridone
Clinical Trials Unit, Rigshospitalet
2015 Phase 2 EUCTR2014-002022-12-SE Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom;
2015 Phase 2 EUCTR2014-002022-12-NL Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom;
2015 Phase 2 EUCTR2014-002022-12-GB Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom;
2015 Phase 2 EUCTR2014-002022-12-BE Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom;
2014 Phase 2 EUCTR2014-002022-12-DK Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom;
2014 Phase 2 EUCTR2014-002022-12-DE Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom;
AZITHROMYCIN DIHYDRATE
KULeuven and University Hospitals Leuven (Leuven Lung Transplant Group)
2010 Phase 4 EUCTR2010-018724-16-BE Belgium;
2009 Phase 4 EUCTR2005-003893-46-BE Belgium;
AZM
Nanfang Hospital of Southern Medical University
2014 Phase 1/Phase 2 NCT02543073 China;
Aerolised Liposomal Ciclosporin A
PARI Pharma GmbH
2012 Phase 3 EUCTR2011-004304-38-GB Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
2012 Phase 3 EUCTR2011-004304-38-DK Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
2012 Phase 3 EUCTR2011-004304-38-BE Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
2012 - EUCTR2011-004304-38-ES Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
2012 - EUCTR2011-004304-38-DE Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
2012 - EUCTR2011-004304-38-AT Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
2010 Phase 3 EUCTR2008-003800-73-BE Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
2009 - EUCTR2008-003800-73-DE Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
2009 - EUCTR2008-003800-73-AT Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
PARIPharma GmbH
2009 - EUCTR2008-003801-15-GB United Kingdom;
- Phase 2 EUCTR2008-003801-15-BE Belgium;United Kingdom;
Pari Pharma GmbH
2010 - EUCTR2008-003800-73-DK Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
2009 Phase 2 EUCTR2008-003800-73-GB Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
Azithromycin
Assistance Publique - Hôpitaux de Paris
2014 Phase 3 NCT01959100 France;
Hospital Authority, Hong Kong
2005 - NCT00563251 China;
Katholieke Universiteit Leuven
2005 Phase 4 NCT01009619 Belgium;
Maisonneuve-Rosemont Hospital
2011 Phase 2 NCT01432080 Canada;
Newcastle upon Tyne Hospitals NHS Trust
2006 - EUCTR2006-000485-36-GB United Kingdom;
Stephanie Lee
2011 Phase 2 NCT01307462 United States;
Azithromycin (Zitromax°)
KULeuven and University Hospitals Leuven
2013 Phase 4 EUCTR2012-003331-32-BE Belgium;
Azithromycin + N-acetylcystein + inhaled corticosteroid
Asan Medical Center
2011 - NCT01327625 Korea, Republic of;
Aztreonam Lysine for Inhalation (AZLI)
Duke University
2013 Phase 4 NCT01469364 United States;
Basiliximab
University Health Network, Toronto
2004 Phase 3 NCT00188825 Canada;
Bortezomib
Northwestern University
2010 Phase 2 NCT01163786 United States;
Budesonide/formoterol
Assistance Publique - Hôpitaux de Paris
2008 Phase 2 NCT01560689 France;
CICLOSPORIN A
BREATH Therapeutics Inc.
2019 Phase 3 EUCTR2018-003205-25-GB Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003205-25-ES Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003204-39-GB France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003204-39-FR France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003204-39-ES France;Germany;Israel;Spain;United Kingdom;United States;
BREATH Therapeutics, Inc.
2020 Phase 3 EUCTR2019-002987-29-FR Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002987-29-ES Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
Breath Therapeutics Inc.
2019 Phase 2 EUCTR2019-000718-13-FR France;Germany;Spain;
2019 Phase 2 EUCTR2019-000718-13-ES Spain;
ZAMBON SpA
2019 Phase 3 EUCTR2018-003204-39-DE France;Germany;Israel;Spain;United Kingdom;United States;
Zambon SpA
2022 Phase 3 EUCTR2018-003205-25-DK Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002987-29-DE Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002987-29-AT Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003205-25-DE Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003205-25-AT Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000718-13-DE France;Germany;Spain;
Certican
St Vincent's Hospital
2005 - EUCTR2004-001290-25-GB Austria;Germany;Spain;United Kingdom;
Certican 0,5 mg Tabletten
Prof Allan Glanville, St Vincents Hospital
2005 - EUCTR2004-001290-25-AT Austria;Germany;Spain;United Kingdom;
Certican 0,75mg Tabletten
Prof Allan Glanville, St Vincents Hospital
2005 - EUCTR2004-001290-25-AT Austria;Germany;Spain;United Kingdom;
Ciclosporin (Ciclosporinium)
BREATH Therapeutics Inc.
2019 Phase 3 EUCTR2018-003205-25-GB Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003205-25-ES Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003204-39-GB France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003204-39-FR France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003204-39-ES France;Germany;Israel;Spain;United Kingdom;United States;
BREATH Therapeutics, Inc.
2020 Phase 3 EUCTR2019-002987-29-FR Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002987-29-ES Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
Breath Therapeutics Inc.
2019 Phase 2 EUCTR2019-000718-13-FR France;Germany;Spain;
2019 Phase 2 EUCTR2019-000718-13-ES Spain;
ZAMBON SpA
2019 Phase 3 EUCTR2018-003204-39-DE France;Germany;Israel;Spain;United Kingdom;United States;
Zambon SpA
2022 Phase 3 EUCTR2018-003205-25-DK Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002987-29-DE Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002987-29-AT Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003205-25-DE Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003205-25-AT Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000718-13-DE France;Germany;Spain;
Ciclosporina / Ciclosporin
Pari Pharma GmbH
2010 - EUCTR2008-003800-73-ES Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
Ciclosporina A Liposomica Aerolised Liposomal Ciclosporin A
Pari Pharma GmbH
2010 - EUCTR2008-003800-73-ES Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
Ciclosporina/ Ciclosporin
Pari Pharma GmbH
2010 - EUCTR2008-003800-73-ES Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
Ciclosporine A
St Vincent’s Hospital, Sydney, Australia
2006 - EUCTR2004-001290-25-DE Germany;Spain;United Kingdom;
Ciclosporine, Ciclosporina
PARI Pharma GmbH
2012 Phase 3 EUCTR2011-004304-38-GB Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
2012 Phase 3 EUCTR2011-004304-38-DK Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
2012 Phase 3 EUCTR2011-004304-38-BE Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
2012 - EUCTR2011-004304-38-ES Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
2012 - EUCTR2011-004304-38-DE Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
2012 - EUCTR2011-004304-38-AT Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
2010 Phase 3 EUCTR2008-003800-73-BE Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
2009 - EUCTR2008-003800-73-DE Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
2009 - EUCTR2008-003800-73-AT Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
Pari Pharma GmbH
2010 - EUCTR2008-003800-73-ES Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
2010 - EUCTR2008-003800-73-DK Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
2009 Phase 2 EUCTR2008-003800-73-GB Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
Ciclosporine, ciclosporina
PARIPharma GmbH
2009 - EUCTR2008-003801-15-GB United Kingdom;
- Phase 2 EUCTR2008-003801-15-BE Belgium;United Kingdom;
Clarithromycin
Baqiyatallah Medical Sciences University
2003 Phase 3 NCT00381147 Iran, Islamic Republic of;
Cyclosporine
Universitätsklinikum Hamburg-Eppendorf
2001 Phase 3 NCT01429844 Australia;Austria;Belgium;Germany;Spain;Switzerland;
Cyclosporine A dry powder inhalation (Drug)
University Medical Centre Groningen
2007 Phase 0 NCT00378677 Netherlands;
Cyclosporine Inhalation Solution
National Heart, Lung, and Blood Institute (NHLBI)
2011 Phase 2 NCT01287078 United States;
Pari Pharma GmbH
2009 Phase 2/Phase 3 NCT01334892 Germany;
Cyclosporine Inhalation Solution (CIS)
APT Pharmaceuticals, Inc.
2008 Phase 3 NCT00755781 Canada;United States;
National Heart, Lung, and Blood Institute (NHLBI)
2012 Phase 2 NCT01273207 United States;
ERL080
Prof Allan Glanville, St Vincents Hospital
2005 - EUCTR2004-001290-25-AT Austria;Germany;Spain;United Kingdom;
Enteric coated mycophenolate sodium
St Vincent’s Hospital, Sydney, Australia
2006 - EUCTR2004-001290-25-DE Germany;Spain;United Kingdom;
Erythromycin
Baqiyatallah Medical Sciences University
2006 Phase 4 NCT00367419 Iran, Islamic Republic of;
Esbriet
Clinical Trials Unit, Rigshospitalet
2015 Phase 2 EUCTR2014-002022-12-SE Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom;
2015 Phase 2 EUCTR2014-002022-12-NL Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom;
2015 Phase 2 EUCTR2014-002022-12-GB Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom;
2015 Phase 2 EUCTR2014-002022-12-BE Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom;
2014 Phase 2 EUCTR2014-002022-12-DK Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom;
2014 Phase 2 EUCTR2014-002022-12-DE Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom;
Etanercept
FDA Office of Orphan Products Development
2001 Phase 1/Phase 2 NCT00029328 United States;
University of Michigan Cancer Center
2003 Phase 2 NCT00141726 United States;
Everolimus
Prof Allan Glanville, St Vincents Hospital
2005 - EUCTR2004-001290-25-AT Austria;Germany;Spain;United Kingdom;
St Vincent’s Hospital, Sydney, Australia
2006 - EUCTR2004-001290-25-DE Germany;Spain;United Kingdom;
FAM Therapy
Ann & Robert H Lurie Children's Hospital of Chicago
2015 - NCT03072849 United States;
Fluticasone propionate
Stephanie Lee
2011 Phase 2 NCT01307462 United States;
Formoterol/Budesonide
Assistance Publique - Hôpitaux de Paris
2008 Phase 2 NCT00624754 France;
Glucocorticoid
Nanfang Hospital of Southern Medical University
2014 Phase 1/Phase 2 NCT02543073 China;
Hp 129Xenon
Children's Hospital Medical Center, Cincinnati
2020 Phase 1/Phase 2 NCT03603899 United States;
Hyperpolarized Helium-3 MRI
Children's Hospital Medical Center, Cincinnati
2014 - NCT02316392 United States;
Imukin
Freistaat Bayern
- - EUCTR2010-022467-36-DE Germany;
Inhalation
Pari Pharma GmbH
2012 Phase 3 NCT01439958 Germany;
Interferon gamma 1b
University Hospital Regensburg
2012 Phase 2 NCT01639261 Germany;
Itacitinib
Incyte Corporation
2020 Phase 1/Phase 2 NCT03978637 Belgium;Canada;United States;
Itacitinib Adipate
M.D. Anderson Cancer Center
2021 Phase 1 NCT04239989 United States;
L-CsA
BREATH Therapeutics Inc.
2019 Phase 3 EUCTR2018-003205-25-GB Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003205-25-ES Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003204-39-GB France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003204-39-FR France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003204-39-ES France;Germany;Israel;Spain;United Kingdom;United States;
BREATH Therapeutics, Inc.
2020 Phase 3 EUCTR2019-002987-29-FR Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002987-29-ES Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
Breath Therapeutics Inc.
2019 Phase 2 EUCTR2019-000718-13-FR France;Germany;Spain;
2019 Phase 2 EUCTR2019-000718-13-ES Spain;
PARI Pharma GmbH
2012 Phase 3 EUCTR2011-004304-38-GB Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
2012 Phase 3 EUCTR2011-004304-38-DK Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
2012 Phase 3 EUCTR2011-004304-38-BE Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
2012 - EUCTR2011-004304-38-ES Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
2012 - EUCTR2011-004304-38-DE Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
2012 - EUCTR2011-004304-38-AT Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
2010 Phase 3 EUCTR2008-003800-73-BE Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
2009 - EUCTR2008-003800-73-DE Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
2009 - EUCTR2008-003800-73-AT Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
PARIPharma GmbH
2009 - EUCTR2008-003801-15-GB United Kingdom;
- Phase 2 EUCTR2008-003801-15-BE Belgium;United Kingdom;
Pari Pharma GmbH
2010 - EUCTR2008-003800-73-ES Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
2010 - EUCTR2008-003800-73-DK Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
2009 Phase 2 EUCTR2008-003800-73-GB Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
ZAMBON SpA
2019 Phase 3 EUCTR2018-003204-39-DE France;Germany;Israel;Spain;United Kingdom;United States;
Zambon SpA
2022 Phase 3 EUCTR2018-003205-25-DK Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002987-29-DE Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002987-29-AT Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003205-25-DE Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003205-25-AT Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000718-13-DE France;Germany;Spain;
Lactose
Assistance Publique - Hôpitaux de Paris
2008 Phase 2 NCT00624754 France;
Liposomal Cyclosporine A
BREATH Therapeutics Inc.
2019 Phase 3 EUCTR2018-003205-25-GB Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003205-25-ES Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003204-39-GB France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003204-39-FR France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003204-39-ES France;Germany;Israel;Spain;United Kingdom;United States;
BREATH Therapeutics, Inc.
2020 Phase 3 EUCTR2019-002987-29-FR Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002987-29-ES Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
Breath Therapeutics Inc.
2019 Phase 2 EUCTR2019-000718-13-FR France;Germany;Spain;
2019 Phase 2 EUCTR2019-000718-13-ES Spain;
ZAMBON SpA
2019 Phase 3 EUCTR2018-003204-39-DE France;Germany;Israel;Spain;United Kingdom;United States;
Zambon SpA
2022 Phase 3 EUCTR2018-003205-25-DK Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States;
2020 Phase 3 NCT04039347 Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002987-29-DE Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002987-29-AT Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2020 Phase 2 NCT04107675 France;Germany;Spain;
2019 Phase 3 NCT03657342 France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 NCT03656926 Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003205-25-DE Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003205-25-AT Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000718-13-DE France;Germany;Spain;
Liposomal aerosol cyclosporine
University of Maryland, College Park
2012 Phase 1/Phase 2 NCT01650545 United States;
MONTELUKAST SODIUM
UZ Gasthuisberg
2010 - EUCTR2010-021983-14-BE Belgium;
MPH966
National Cancer Institute (NCI)
2016 Phase 1/Phase 2 NCT02669251 United States;
MSCs
Nanfang Hospital of Southern Medical University
2014 Phase 1/Phase 2 NCT02543073 China;
Mesenchymal stem cell 0.5
Mayo Clinic
2014 Phase 1 NCT02181712 United States;
Mesenchymal stem cell 1.0
Mayo Clinic
2014 Phase 1 NCT02181712 United States;
Montelukast
Maisonneuve-Rosemont Hospital
2011 Phase 2 NCT01432080 Canada;
Universitaire Ziekenhuizen Leuven
2010 Phase 4 NCT01211509 Belgium;
Montelukast sodium
Stephanie Lee
2011 Phase 2 NCT01307462 United States;
Mycophenolate
Prof Allan Glanville, St Vincents Hospital
2005 - EUCTR2004-001290-25-AT Austria;Germany;Spain;United Kingdom;
Myfortic
Prof Allan Glanville, St Vincents Hospital
2005 - EUCTR2004-001290-25-AT Austria;Germany;Spain;United Kingdom;
St Vincent's Hospital
2005 - EUCTR2004-001290-25-GB Austria;Germany;Spain;United Kingdom;
Nintedanib
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2019 Phase 3 EUCTR2018-001747-31-FR France;
Assistance Publique - Hôpitaux de Paris
2019 Phase 3 NCT03283007 France;
University Hospital, Basel, Switzerland
2019 Phase 2 NCT03805477 Austria;Germany;Switzerland;
OFEV
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2019 Phase 3 EUCTR2018-001747-31-FR France;
OTHER SOURCES
KULeuven and University Hospitals Leuven (Leuven Lung Transplant Group)
2010 Phase 4 EUCTR2010-018724-16-BE Belgium;
Pirfenidone
Rigshospitalet, Denmark
2015 Phase 2/Phase 3 NCT02262299 Belgium;Denmark;Germany;Netherlands;Norway;Sweden;United Kingdom;
Pirfenidone 267 MG [Esbriet]
Stanford University
2018 Phase 1 NCT03315741 United States;
Prednisone
Maisonneuve-Rosemont Hospital
2011 Phase 2 NCT01432080 Canada;
Pulmonary function testing
Ann & Robert H Lurie Children's Hospital of Chicago
2015 - NCT03072849 United States;
RAD001
Prof Allan Glanville, St Vincents Hospital
2005 - EUCTR2004-001290-25-AT Austria;Germany;Spain;United Kingdom;
Ruxolitinib
Children's Hospital Medical Center, Cincinnati
2021 Phase 2 NCT04908735 United States;
Massachusetts General Hospital
2019 Phase 2 NCT03674047 United States;
Salbutamol
Guy's and St Thomas' NHS Foundation Trust
2016 - NCT02863835 United Kingdom;
Seretide
Assistance Publique - Hôpitaux de Paris
2021 Phase 3 NCT04655508 France;
Singulair
UZ Gasthuisberg
2010 - EUCTR2010-021983-14-BE Belgium;
Singulair (Montelukast Sodium)
National Cancer Institute (NCI)
2008 Phase 2 NCT00656058 United States;
Sodium Chloride Solution
PARI Pharma GmbH
2010 Phase 3 EUCTR2008-003800-73-BE Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
2009 - EUCTR2008-003800-73-DE Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
2009 - EUCTR2008-003800-73-AT Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
PARIPharma GmbH
2009 - EUCTR2008-003801-15-GB United Kingdom;
- Phase 2 EUCTR2008-003801-15-BE Belgium;United Kingdom;
Pari Pharma GmbH
2010 - EUCTR2008-003800-73-DK Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
2009 Phase 2 EUCTR2008-003800-73-GB Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
Sodium Chloride Solvent
PARI Pharma GmbH
2010 Phase 3 EUCTR2008-003800-73-BE Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
2009 - EUCTR2008-003800-73-DE Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
2009 - EUCTR2008-003800-73-AT Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
Pari Pharma GmbH
2010 - EUCTR2008-003800-73-DK Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
2009 Phase 2 EUCTR2008-003800-73-GB Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
Sodium Chloride solvent
PARIPharma GmbH
2009 - EUCTR2008-003801-15-GB United Kingdom;
- Phase 2 EUCTR2008-003801-15-BE Belgium;United Kingdom;
Solucion de cloruro de sodio Sodium Chloride Solution
Pari Pharma GmbH
2010 - EUCTR2008-003800-73-ES Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
Solvente Cloruro de Sodio Sodium Chloride Solvent
Pari Pharma GmbH
2010 - EUCTR2008-003800-73-ES Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
Solvente de Cloruro de Sodio
Pari Pharma GmbH
2010 - EUCTR2008-003800-73-ES Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
Status Post Lung Transplant
Duke University
2013 Phase 4 NCT01469364 United States;
Symbicort
Maisonneuve-Rosemont Hospital
2011 Phase 2 NCT01432080 Canada;
Tacrolimus
Universitätsklinikum Hamburg-Eppendorf
2001 Phase 3 NCT01429844 Australia;Austria;Belgium;Germany;Spain;Switzerland;
Vitamin D
Universitaire Ziekenhuizen Leuven
2010 Phase 4 NCT01212406 Belgium;
Xenon
Hamilton Health Sciences Corporation
2019 - NCT04029636 Canada;
Zithromax
KULeuven and University Hospitals Leuven (Leuven Lung Transplant Group)
2009 Phase 4 EUCTR2005-003893-46-BE Belgium;
Zitromax
KULeuven and University Hospitals Leuven (Leuven Lung Transplant Group)
2010 Phase 4 EUCTR2010-018724-16-BE Belgium;
Clinical Trials Unit, Rigshospitalet
2015 Phase 2 EUCTR2014-002022-12-SE Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom;
2015 Phase 2 EUCTR2014-002022-12-NL Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom;
2015 Phase 2 EUCTR2014-002022-12-GB Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom;
2015 Phase 2 EUCTR2014-002022-12-BE Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom;
2014 Phase 2 EUCTR2014-002022-12-DK Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom;
2014 Phase 2 EUCTR2014-002022-12-DE Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom;
AZITHROMYCIN DIHYDRATE
KULeuven and University Hospitals Leuven (Leuven Lung Transplant Group)
2010 Phase 4 EUCTR2010-018724-16-BE Belgium;
2009 Phase 4 EUCTR2005-003893-46-BE Belgium;
AZM
Nanfang Hospital of Southern Medical University
2014 Phase 1/Phase 2 NCT02543073 China;
Aerolised Liposomal Ciclosporin A
PARI Pharma GmbH
2012 Phase 3 EUCTR2011-004304-38-GB Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
2012 Phase 3 EUCTR2011-004304-38-DK Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
2012 Phase 3 EUCTR2011-004304-38-BE Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
2012 - EUCTR2011-004304-38-ES Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
2012 - EUCTR2011-004304-38-DE Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
2012 - EUCTR2011-004304-38-AT Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
2010 Phase 3 EUCTR2008-003800-73-BE Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
2009 - EUCTR2008-003800-73-DE Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
2009 - EUCTR2008-003800-73-AT Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
PARIPharma GmbH
2009 - EUCTR2008-003801-15-GB United Kingdom;
- Phase 2 EUCTR2008-003801-15-BE Belgium;United Kingdom;
Pari Pharma GmbH
2010 - EUCTR2008-003800-73-DK Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
2009 Phase 2 EUCTR2008-003800-73-GB Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
Azithromycin
Assistance Publique - Hôpitaux de Paris
2014 Phase 3 NCT01959100 France;
Hospital Authority, Hong Kong
2005 - NCT00563251 China;
Katholieke Universiteit Leuven
2005 Phase 4 NCT01009619 Belgium;
Maisonneuve-Rosemont Hospital
2011 Phase 2 NCT01432080 Canada;
Newcastle upon Tyne Hospitals NHS Trust
2006 - EUCTR2006-000485-36-GB United Kingdom;
Stephanie Lee
2011 Phase 2 NCT01307462 United States;
Azithromycin (Zitromax°)
KULeuven and University Hospitals Leuven
2013 Phase 4 EUCTR2012-003331-32-BE Belgium;
Azithromycin + N-acetylcystein + inhaled corticosteroid
Asan Medical Center
2011 - NCT01327625 Korea, Republic of;
Aztreonam Lysine for Inhalation (AZLI)
Duke University
2013 Phase 4 NCT01469364 United States;
Basiliximab
University Health Network, Toronto
2004 Phase 3 NCT00188825 Canada;
Bortezomib
Northwestern University
2010 Phase 2 NCT01163786 United States;
Budesonide/formoterol
Assistance Publique - Hôpitaux de Paris
2008 Phase 2 NCT01560689 France;
CICLOSPORIN A
BREATH Therapeutics Inc.
2019 Phase 3 EUCTR2018-003205-25-GB Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003205-25-ES Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003204-39-GB France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003204-39-FR France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003204-39-ES France;Germany;Israel;Spain;United Kingdom;United States;
BREATH Therapeutics, Inc.
2020 Phase 3 EUCTR2019-002987-29-FR Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002987-29-ES Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
Breath Therapeutics Inc.
2019 Phase 2 EUCTR2019-000718-13-FR France;Germany;Spain;
2019 Phase 2 EUCTR2019-000718-13-ES Spain;
ZAMBON SpA
2019 Phase 3 EUCTR2018-003204-39-DE France;Germany;Israel;Spain;United Kingdom;United States;
Zambon SpA
2022 Phase 3 EUCTR2018-003205-25-DK Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002987-29-DE Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002987-29-AT Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003205-25-DE Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003205-25-AT Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000718-13-DE France;Germany;Spain;
Certican
St Vincent's Hospital
2005 - EUCTR2004-001290-25-GB Austria;Germany;Spain;United Kingdom;
Certican 0,5 mg Tabletten
Prof Allan Glanville, St Vincents Hospital
2005 - EUCTR2004-001290-25-AT Austria;Germany;Spain;United Kingdom;
Certican 0,75mg Tabletten
Prof Allan Glanville, St Vincents Hospital
2005 - EUCTR2004-001290-25-AT Austria;Germany;Spain;United Kingdom;
Ciclosporin (Ciclosporinium)
BREATH Therapeutics Inc.
2019 Phase 3 EUCTR2018-003205-25-GB Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003205-25-ES Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003204-39-GB France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003204-39-FR France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003204-39-ES France;Germany;Israel;Spain;United Kingdom;United States;
BREATH Therapeutics, Inc.
2020 Phase 3 EUCTR2019-002987-29-FR Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002987-29-ES Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
Breath Therapeutics Inc.
2019 Phase 2 EUCTR2019-000718-13-FR France;Germany;Spain;
2019 Phase 2 EUCTR2019-000718-13-ES Spain;
ZAMBON SpA
2019 Phase 3 EUCTR2018-003204-39-DE France;Germany;Israel;Spain;United Kingdom;United States;
Zambon SpA
2022 Phase 3 EUCTR2018-003205-25-DK Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002987-29-DE Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002987-29-AT Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003205-25-DE Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003205-25-AT Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000718-13-DE France;Germany;Spain;
Ciclosporina / Ciclosporin
Pari Pharma GmbH
2010 - EUCTR2008-003800-73-ES Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
Ciclosporina A Liposomica Aerolised Liposomal Ciclosporin A
Pari Pharma GmbH
2010 - EUCTR2008-003800-73-ES Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
Ciclosporina/ Ciclosporin
Pari Pharma GmbH
2010 - EUCTR2008-003800-73-ES Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
Ciclosporine A
St Vincent’s Hospital, Sydney, Australia
2006 - EUCTR2004-001290-25-DE Germany;Spain;United Kingdom;
Ciclosporine, Ciclosporina
PARI Pharma GmbH
2012 Phase 3 EUCTR2011-004304-38-GB Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
2012 Phase 3 EUCTR2011-004304-38-DK Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
2012 Phase 3 EUCTR2011-004304-38-BE Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
2012 - EUCTR2011-004304-38-ES Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
2012 - EUCTR2011-004304-38-DE Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
2012 - EUCTR2011-004304-38-AT Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
2010 Phase 3 EUCTR2008-003800-73-BE Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
2009 - EUCTR2008-003800-73-DE Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
2009 - EUCTR2008-003800-73-AT Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
Pari Pharma GmbH
2010 - EUCTR2008-003800-73-ES Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
2010 - EUCTR2008-003800-73-DK Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
2009 Phase 2 EUCTR2008-003800-73-GB Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
Ciclosporine, ciclosporina
PARIPharma GmbH
2009 - EUCTR2008-003801-15-GB United Kingdom;
- Phase 2 EUCTR2008-003801-15-BE Belgium;United Kingdom;
Clarithromycin
Baqiyatallah Medical Sciences University
2003 Phase 3 NCT00381147 Iran, Islamic Republic of;
Cyclosporine
Universitätsklinikum Hamburg-Eppendorf
2001 Phase 3 NCT01429844 Australia;Austria;Belgium;Germany;Spain;Switzerland;
Cyclosporine A dry powder inhalation (Drug)
University Medical Centre Groningen
2007 Phase 0 NCT00378677 Netherlands;
Cyclosporine Inhalation Solution
National Heart, Lung, and Blood Institute (NHLBI)
2011 Phase 2 NCT01287078 United States;
Pari Pharma GmbH
2009 Phase 2/Phase 3 NCT01334892 Germany;
Cyclosporine Inhalation Solution (CIS)
APT Pharmaceuticals, Inc.
2008 Phase 3 NCT00755781 Canada;United States;
National Heart, Lung, and Blood Institute (NHLBI)
2012 Phase 2 NCT01273207 United States;
ERL080
Prof Allan Glanville, St Vincents Hospital
2005 - EUCTR2004-001290-25-AT Austria;Germany;Spain;United Kingdom;
Enteric coated mycophenolate sodium
St Vincent’s Hospital, Sydney, Australia
2006 - EUCTR2004-001290-25-DE Germany;Spain;United Kingdom;
Erythromycin
Baqiyatallah Medical Sciences University
2006 Phase 4 NCT00367419 Iran, Islamic Republic of;
Esbriet
Clinical Trials Unit, Rigshospitalet
2015 Phase 2 EUCTR2014-002022-12-SE Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom;
2015 Phase 2 EUCTR2014-002022-12-NL Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom;
2015 Phase 2 EUCTR2014-002022-12-GB Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom;
2015 Phase 2 EUCTR2014-002022-12-BE Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom;
2014 Phase 2 EUCTR2014-002022-12-DK Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom;
2014 Phase 2 EUCTR2014-002022-12-DE Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom;
Etanercept
FDA Office of Orphan Products Development
2001 Phase 1/Phase 2 NCT00029328 United States;
University of Michigan Cancer Center
2003 Phase 2 NCT00141726 United States;
Everolimus
Prof Allan Glanville, St Vincents Hospital
2005 - EUCTR2004-001290-25-AT Austria;Germany;Spain;United Kingdom;
St Vincent’s Hospital, Sydney, Australia
2006 - EUCTR2004-001290-25-DE Germany;Spain;United Kingdom;
FAM Therapy
Ann & Robert H Lurie Children's Hospital of Chicago
2015 - NCT03072849 United States;
Fluticasone propionate
Stephanie Lee
2011 Phase 2 NCT01307462 United States;
Formoterol/Budesonide
Assistance Publique - Hôpitaux de Paris
2008 Phase 2 NCT00624754 France;
Glucocorticoid
Nanfang Hospital of Southern Medical University
2014 Phase 1/Phase 2 NCT02543073 China;
Hp 129Xenon
Children's Hospital Medical Center, Cincinnati
2020 Phase 1/Phase 2 NCT03603899 United States;
Hyperpolarized Helium-3 MRI
Children's Hospital Medical Center, Cincinnati
2014 - NCT02316392 United States;
Imukin
Freistaat Bayern
- - EUCTR2010-022467-36-DE Germany;
Inhalation
Pari Pharma GmbH
2012 Phase 3 NCT01439958 Germany;
Interferon gamma 1b
University Hospital Regensburg
2012 Phase 2 NCT01639261 Germany;
Itacitinib
Incyte Corporation
2020 Phase 1/Phase 2 NCT03978637 Belgium;Canada;United States;
Itacitinib Adipate
M.D. Anderson Cancer Center
2021 Phase 1 NCT04239989 United States;
L-CsA
BREATH Therapeutics Inc.
2019 Phase 3 EUCTR2018-003205-25-GB Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003205-25-ES Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003204-39-GB France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003204-39-FR France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003204-39-ES France;Germany;Israel;Spain;United Kingdom;United States;
BREATH Therapeutics, Inc.
2020 Phase 3 EUCTR2019-002987-29-FR Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002987-29-ES Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
Breath Therapeutics Inc.
2019 Phase 2 EUCTR2019-000718-13-FR France;Germany;Spain;
2019 Phase 2 EUCTR2019-000718-13-ES Spain;
PARI Pharma GmbH
2012 Phase 3 EUCTR2011-004304-38-GB Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
2012 Phase 3 EUCTR2011-004304-38-DK Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
2012 Phase 3 EUCTR2011-004304-38-BE Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
2012 - EUCTR2011-004304-38-ES Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
2012 - EUCTR2011-004304-38-DE Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
2012 - EUCTR2011-004304-38-AT Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
2010 Phase 3 EUCTR2008-003800-73-BE Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
2009 - EUCTR2008-003800-73-DE Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
2009 - EUCTR2008-003800-73-AT Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
PARIPharma GmbH
2009 - EUCTR2008-003801-15-GB United Kingdom;
- Phase 2 EUCTR2008-003801-15-BE Belgium;United Kingdom;
Pari Pharma GmbH
2010 - EUCTR2008-003800-73-ES Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
2010 - EUCTR2008-003800-73-DK Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
2009 Phase 2 EUCTR2008-003800-73-GB Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
ZAMBON SpA
2019 Phase 3 EUCTR2018-003204-39-DE France;Germany;Israel;Spain;United Kingdom;United States;
Zambon SpA
2022 Phase 3 EUCTR2018-003205-25-DK Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002987-29-DE Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002987-29-AT Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003205-25-DE Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003205-25-AT Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000718-13-DE France;Germany;Spain;
Lactose
Assistance Publique - Hôpitaux de Paris
2008 Phase 2 NCT00624754 France;
Liposomal Cyclosporine A
BREATH Therapeutics Inc.
2019 Phase 3 EUCTR2018-003205-25-GB Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003205-25-ES Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003204-39-GB France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003204-39-FR France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003204-39-ES France;Germany;Israel;Spain;United Kingdom;United States;
BREATH Therapeutics, Inc.
2020 Phase 3 EUCTR2019-002987-29-FR Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002987-29-ES Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
Breath Therapeutics Inc.
2019 Phase 2 EUCTR2019-000718-13-FR France;Germany;Spain;
2019 Phase 2 EUCTR2019-000718-13-ES Spain;
ZAMBON SpA
2019 Phase 3 EUCTR2018-003204-39-DE France;Germany;Israel;Spain;United Kingdom;United States;
Zambon SpA
2022 Phase 3 EUCTR2018-003205-25-DK Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States;
2020 Phase 3 NCT04039347 Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002987-29-DE Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002987-29-AT Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2020 Phase 2 NCT04107675 France;Germany;Spain;
2019 Phase 3 NCT03657342 France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 NCT03656926 Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003205-25-DE Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003205-25-AT Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000718-13-DE France;Germany;Spain;
Liposomal aerosol cyclosporine
University of Maryland, College Park
2012 Phase 1/Phase 2 NCT01650545 United States;
MONTELUKAST SODIUM
UZ Gasthuisberg
2010 - EUCTR2010-021983-14-BE Belgium;
MPH966
National Cancer Institute (NCI)
2016 Phase 1/Phase 2 NCT02669251 United States;
MSCs
Nanfang Hospital of Southern Medical University
2014 Phase 1/Phase 2 NCT02543073 China;
Mesenchymal stem cell 0.5
Mayo Clinic
2014 Phase 1 NCT02181712 United States;
Mesenchymal stem cell 1.0
Mayo Clinic
2014 Phase 1 NCT02181712 United States;
Montelukast
Maisonneuve-Rosemont Hospital
2011 Phase 2 NCT01432080 Canada;
Universitaire Ziekenhuizen Leuven
2010 Phase 4 NCT01211509 Belgium;
Montelukast sodium
Stephanie Lee
2011 Phase 2 NCT01307462 United States;
Mycophenolate
Prof Allan Glanville, St Vincents Hospital
2005 - EUCTR2004-001290-25-AT Austria;Germany;Spain;United Kingdom;
Myfortic
Prof Allan Glanville, St Vincents Hospital
2005 - EUCTR2004-001290-25-AT Austria;Germany;Spain;United Kingdom;
St Vincent's Hospital
2005 - EUCTR2004-001290-25-GB Austria;Germany;Spain;United Kingdom;
Nintedanib
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2019 Phase 3 EUCTR2018-001747-31-FR France;
Assistance Publique - Hôpitaux de Paris
2019 Phase 3 NCT03283007 France;
University Hospital, Basel, Switzerland
2019 Phase 2 NCT03805477 Austria;Germany;Switzerland;
OFEV
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2019 Phase 3 EUCTR2018-001747-31-FR France;
OTHER SOURCES
KULeuven and University Hospitals Leuven (Leuven Lung Transplant Group)
2010 Phase 4 EUCTR2010-018724-16-BE Belgium;
Pirfenidone
Rigshospitalet, Denmark
2015 Phase 2/Phase 3 NCT02262299 Belgium;Denmark;Germany;Netherlands;Norway;Sweden;United Kingdom;
Pirfenidone 267 MG [Esbriet]
Stanford University
2018 Phase 1 NCT03315741 United States;
Prednisone
Maisonneuve-Rosemont Hospital
2011 Phase 2 NCT01432080 Canada;
Pulmonary function testing
Ann & Robert H Lurie Children's Hospital of Chicago
2015 - NCT03072849 United States;
RAD001
Prof Allan Glanville, St Vincents Hospital
2005 - EUCTR2004-001290-25-AT Austria;Germany;Spain;United Kingdom;
Ruxolitinib
Children's Hospital Medical Center, Cincinnati
2021 Phase 2 NCT04908735 United States;
Massachusetts General Hospital
2019 Phase 2 NCT03674047 United States;
Salbutamol
Guy's and St Thomas' NHS Foundation Trust
2016 - NCT02863835 United Kingdom;
Seretide
Assistance Publique - Hôpitaux de Paris
2021 Phase 3 NCT04655508 France;
Singulair
UZ Gasthuisberg
2010 - EUCTR2010-021983-14-BE Belgium;
Singulair (Montelukast Sodium)
National Cancer Institute (NCI)
2008 Phase 2 NCT00656058 United States;
Sodium Chloride Solution
PARI Pharma GmbH
2010 Phase 3 EUCTR2008-003800-73-BE Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
2009 - EUCTR2008-003800-73-DE Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
2009 - EUCTR2008-003800-73-AT Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
PARIPharma GmbH
2009 - EUCTR2008-003801-15-GB United Kingdom;
- Phase 2 EUCTR2008-003801-15-BE Belgium;United Kingdom;
Pari Pharma GmbH
2010 - EUCTR2008-003800-73-DK Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
2009 Phase 2 EUCTR2008-003800-73-GB Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
Sodium Chloride Solvent
PARI Pharma GmbH
2010 Phase 3 EUCTR2008-003800-73-BE Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
2009 - EUCTR2008-003800-73-DE Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
2009 - EUCTR2008-003800-73-AT Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
Pari Pharma GmbH
2010 - EUCTR2008-003800-73-DK Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
2009 Phase 2 EUCTR2008-003800-73-GB Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
Sodium Chloride solvent
PARIPharma GmbH
2009 - EUCTR2008-003801-15-GB United Kingdom;
- Phase 2 EUCTR2008-003801-15-BE Belgium;United Kingdom;
Solucion de cloruro de sodio Sodium Chloride Solution
Pari Pharma GmbH
2010 - EUCTR2008-003800-73-ES Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
Solvente Cloruro de Sodio Sodium Chloride Solvent
Pari Pharma GmbH
2010 - EUCTR2008-003800-73-ES Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
Solvente de Cloruro de Sodio
Pari Pharma GmbH
2010 - EUCTR2008-003800-73-ES Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
Status Post Lung Transplant
Duke University
2013 Phase 4 NCT01469364 United States;
Symbicort
Maisonneuve-Rosemont Hospital
2011 Phase 2 NCT01432080 Canada;
Tacrolimus
Universitätsklinikum Hamburg-Eppendorf
2001 Phase 3 NCT01429844 Australia;Austria;Belgium;Germany;Spain;Switzerland;
Vitamin D
Universitaire Ziekenhuizen Leuven
2010 Phase 4 NCT01212406 Belgium;
Xenon
Hamilton Health Sciences Corporation
2019 - NCT04029636 Canada;
Zithromax
KULeuven and University Hospitals Leuven (Leuven Lung Transplant Group)
2009 Phase 4 EUCTR2005-003893-46-BE Belgium;
Zitromax
KULeuven and University Hospitals Leuven (Leuven Lung Transplant Group)
2010 Phase 4 EUCTR2010-018724-16-BE Belgium;